Autoinjectors Market - By Type (Disposable, Reusable), By Route of Administration (Subcutaneous, Intramuscular), By Therapy, (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes, Oncology, Asthma, Migraine, Hormone Therapy), By End-use (Hospit

Autoinjectors Market - By Type (Disposable, Reusable), By Route of Administration (Subcutaneous, Intramuscular), By Therapy, (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes, Oncology, Asthma, Migraine, Hormone Therapy), By End-use (Hospital & Clinics, Homecare Settings) & Global Forecast, 2023 - 2032

Global Autoinjectors Market is slated to grow exponentially by 2032, owing to the rising demand for targeted therapies, in light of the growing prevalence of chronic diseases. In addition, introduction to novel targeted medicines and investments in drug development is slated to drive the growth of the autoinjectors market.

Besides, the rising preference for self-administration medication would propel the market demand in the ensuing years. Moreover, the increasing requirement to reduce the time and risk and expense of modifying designs that could be used across large biologic pharmaceutical portfolios are anticipated to foster the product adoption worldwide.

The key players in the global autoinjector industry are continuously incorporating strategic initiatives such as mergers and acquisitions, partnerships, and introducing reusable autoinjectors with disposable cassettes and electronic drive units. These reusable autoinjectors contain prefilled syringes and provide needle safety while maximizing the use of novel drugs. Such developments encourage more patients to use autoinjectors for self-administered medications, further augmenting market expansion.

Overall, the global autoinjectors market is bifurcated in terms of type, route of administration, therapy, end-use, and region.

Considering the type, the disposables segment held over USD 37 billion revenue share in 2022 and is slated to demonstrate massive growth through 2032. The growth can be attributed to the exceptional features offered by disposable autoinjectors, such as being patient-centric and easy operability to support the complete injection of medication.

By route of administration, the intramuscular autoinjectors segment is slated to grow considerably owing to its use for anaphylaxis and allergic reactions. In addition, these autoinjectors play a key role during an emergency, which will further support the segmental expansion.

Based on therapy, the diabetes segment held more than 23% market share in 2022 and is expected to grow exponentially through 2032. The growth can be credited to the rising cases and subsequent increase in expenses of diabetes. As per WHO estimates, approximately 422 million people suffer from diabetes.

By end-use, the homecare settings segment is depicted to grow notably during 2023-2032, owing to the benefits offered by autoinjectors, including managing anaphylaxis, diabetes, acute seizures, anxiety, and others. In addition, the product’s capabilities, such as being easy usage, controlled dosage, and self-administrability, are further expected to support the segmental expansion in the future.

Regionally, the Europe global autoinjectors market is slated to exhibit over 20% market share between 2023-2032. The rising medical device industry, changes in the regulatory framework and transparency in the clinical trials/evidence are some key factors that are estimated to stimulate the Europe autoinjector industry growth.